ReviewBioMed research international2019
Biomarkers of Community-Acquired Pneumonia: A Key to Disease Diagnosis and Management.
Review in BioMed research international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04595526 (Optimal Collection of Specimens of the Lower Respiratory Tract), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Optimal Collection of Specimens of the Lower Respiratory Tract
Who cites it
13 citing papers in PubMed.
- Trial
- Prevalence, associated factors and treatment prescriptions for community-acquired pneumonia: a cross-sectional study at the largest children's hospital in the Ashanti Region, Ghana.BMC infectious diseases · 2026Article
- Respiratory delivered vaccines: Current status and perspectives in rational formulation design.Acta pharmaceutica Sinica. B · 2024Review
- Change for the Better: Severe Pneumonia at the Emergency Department.Pathogens (Basel, Switzerland) · 2022Article
- Mapping theme trends and recognizing hot spots in viral pneumonia: a bibliometric analysis of global research.American journal of translational research · 2022Article
- Association of Clinical Signs, Host Biomarkers and Etiology With Radiological Pneumonia in Bhutanese Children.Global pediatric health · 2022Article
- Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia.Current pharmacology reports · 2022Review
- Classification and Drug Resistance Analysis of Pathogenic Bacteria in Patients with Bacterial Pneumonia in Emergency Intensive Care Unit.Contrast media & molecular imaging · 2022Article
- An AI-based auxiliary empirical antibiotic therapy model for children with bacterial pneumonia using low-dose chest CT images.Japanese journal of radiology · 2021Article
- Improved diagnostics of infectious diseases in emergency departments: a protocol of a multifaceted multicentre diagnostic study.BMJ open · 2021Article
- Hepcidin and Ferritin Predict Microbial Etiology in Community-Acquired Pneumonia.Open forum infectious diseases · 2021Article
- [Diagnostic value of serum amyloid A, procalcitonin and hypersensitive C-reactive protein for pulmonary tuberculosis complicated by pneumonia].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Multiresistant Bacterial Pathogens Causing Bacterial Pneumonia and Analyses of Potential Risk Factors from Northeast Ethiopia.International journal of microbiology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Community-acquired pneumonia (CAP) is a dangerous disease caused by a spectrum of bacterial and viral pathogens. The choice of specific therapy and the need for hospitalization or transfer to the intensive care unit are determined by the causative agent and disease severity. The microbiological analysis of sputum largely depends on the quality of the material obtained. The prediction of severity and the duration of therapy are determined individually, and existing prognostic scales are used generally. This review examines the possibilities of using specific serological biomarkers to detect the bacterial or viral aetiology of CAP and to assess disease severity. Particular emphasis is placed on the use of biomarker signatures and the discovery of biomarker candidates for a single multiplex analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.